-

Pattern Bioscience Pneumonia ID/AST Panel Now in Early Evaluation at 5 U.S. Clinical Laboratories

Early Evaluation Program places Pattern’s single-cell microbiology platform in clinical microbiology laboratories to assess the Pneumonia ID/AST Panel within routine workflows.

AUSTIN, Texas--(BUSINESS WIRE)--Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, today announced that its Pneumonia ID/AST Panel is now being evaluated at five clinical microbiology laboratories across the United States through the company’s Early Evaluation Program (EEP).

The Early Evaluation Program gives laboratory directors, medical laboratory scientists, and their clinical partners hands-on experience with Pattern’s platform in their own laboratories. Feedback from the participating sites on workflow, pathways for integration into laboratory workflows, and usability will support Pattern’s plans for commercial introduction of the system. There are additional laboratories in the planning phase, and Pattern expects the program to expand in the coming months.

“We appreciate the partnership of our early evaluation sites. Through these collaborations, we will continue to learn how laboratories will integrate the Pattern system into their routine workflow, and we will generate additional data to help quantify the potential impact of the platform,” said Carey-Ann Burnham, PhD, Chief Executive Officer of Pattern Bioscience.

Pneumonia is a leading cause of sepsis and carries among the highest mortality of sepsis-related infections. Yet clinical laboratories and the clinicians they support often wait two to four days for conventional culture-based methods to return pathogen identification and antimicrobial susceptibility results, a delay that can contribute to prolonged ICU stays, suboptimal antibiotic use and the spread of antimicrobial resistance.

Pattern’s Pneumonia ID/AST Panel is designed to deliver the answers laboratories and clinicians rely on from culture to support the diagnosis of pneumonia: what organism is causing it, and which antibiotics will treat it. It does this by providing bacterial detection, identification, and antimicrobial susceptibility for pathogens in one test, directly from lower respiratory tract specimens. The assay runs on Pattern’s single-cell microbiology platform, which is designed to provide these results in hours rather than the days culture requires. Pattern Bioscience’s products are for Investigational Use Only, and the products have not been cleared by the FDA. Results generated during the Early Evaluation Program are not used for patient management.

The Pneumonia ID/AST Panel has been granted Breakthrough Device Designation by the FDA. Subject to FDA clearance, the company plans to launch the Pneumonia ID/AST Panel as its first commercial product.

About Pattern Bioscience

Pattern Bioscience aims to save lives by transforming how bacterial infections are diagnosed and to improve global health by reducing the burden of antibiotic resistance. Its single-cell microbiology technology is a direct-from-specimen, rapid phenotypic testing platform designed to deliver clinically actionable results in hours, compared to the days required by traditional culture-based methods. Pattern Bioscience is a privately held company based in Austin, Texas, and is led by veterans of the diagnostic industry with deep experience bringing new diagnostic technologies to market. For more information, visit pattern.bio.

Breakthrough Device Designation does not constitute FDA clearance or approval and does not guarantee that the FDA will clear or approve the device, or that any clearance will be obtained within a particular timeframe. Pattern Bioscience’s products are for Investigational Use Only; the performance characteristics of these products have not been established, and the products have not been cleared or approved by the FDA.

Contacts

Media Contact
Eric Berger
eric.berger@pattern.bio

Pattern Bioscience


Release Versions

Contacts

Media Contact
Eric Berger
eric.berger@pattern.bio

Social Media Profiles
More News From Pattern Bioscience

Pattern Bioscience Receives FDA Breakthrough Device Designation for Urine ID/AST Panel

AUSTIN, Texas--(BUSINESS WIRE)--Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Urine ID/AST Panel. The Urine ID/AST Panel is the company’s second assay to receive the designation, following the Pneumonia ID/AST Panel. It reflects Pattern’s continued focus on expansion of a menu of rapid, direct-from-specimen assays.The FDA's Breakthroug...
Back to Newsroom